WuXi AppTec Co Ltd

WuXi AppTec Co Ltd

603259 · SHG · Healthcare / Diagnostics & Research

146.30CNY-4.04 (-2.69%)

Price History

Full chart

Market Stats

Previous Close150.34
Open148.84
Day Range145.87 – 150.38
52-Week Range87.09 – 173.60
Volume27.67M
Market Cap411.72B
P/E (TTM)15.52
Forward P/E14.41
EPS8.74
Dividend Yield1.51%
Beta0.61
50-Day Avg156.02
200-Day Avg121.81

About

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Ge Li Ph.D.
  • Employees33.83K
  • Headquarters288 Fute Zhong Road, Shanghai, China, 200131, China
  • Websitehttps://www.wuxiapptec.com

Leadership

  • Dr. Ge Li Ph.D.Co-Founder, Executive Chairman, President & CEO · b. 1967
  • Dr. Minzhang Chen Ph.D.Co-CEO & Executive Director · b. 1969
  • Dr. Qing Yang Ph.D.Co-CEO & Executive Director · b. 1969
  • Ms. Ming ShiSenior VP & CFO · b. 1974
  • Mr. Zhaohui ZhangCOO of China, Executive VP & Executive Director · b. 1969
  • Mr. Ruijia TangIR Director
  • Dr. Howard Wu J.D.Senior Vice President of Legal Department & Human Resources Department
  • Mr. Tao Guo Ph.D.Senior Vice President of RCS IPM
  • Dr. Youchu Wang Ph.D.Senior Vice President of API Early Phase Development
  • Mr. Feng ZhangSenior Vice President of API Manufacturing · b. 1977

Financials

Income Statement

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.14B4.88B6.12B7.77B9.61B12.87B16.54B22.90B39.35B38.68B37.92B43.42B
Growth (%)-+17.96%+25.24%+26.96%+23.80%+33.89%+28.46%+38.50%+71.84%-1.72%-1.97%+14.51%
Cost of Revenue2.62B3.20B3.63B4.52B5.82B7.86B10.27B14.63B24.72B23.77B21.43B22.45B
Gross Profit1.52B1.68B2.49B3.25B3.79B5.01B6.26B8.28B14.64B14.91B16.49B20.97B
Gross Margin36.69%34.45%40.72%41.82%39.43%38.94%37.88%36.14%37.19%38.55%43.49%48.30%
Operating Expense656.77M910.63M1.21B1.79B1.21B2.67B2.87B2.24B3.98B3.04B3.07B4.98B
Operating Income861.96M771.68M1.28B1.46B2.58B2.34B3.39B6.04B10.65B11.87B13.42B15.99B
Operating Margin20.82%15.80%21.00%18.81%26.89%18.19%20.50%26.36%27.07%30.70%35.39%36.82%
EBITDA-806.61M1.57B2.05B2.39B3.27B3.91B5.42B10.64B11.89B14.55B19.50B
EBITDA Margin-16.52%25.60%26.40%24.81%25.38%23.67%23.68%27.04%30.73%38.36%44.91%
Net Income461.50M348.97M974.98M1.23B2.26B1.85B2.96B5.10B8.81B9.61B9.45B19.19B
Net Income Margin11.15%7.15%15.94%15.80%23.51%14.41%17.90%22.26%22.40%24.84%24.92%44.19%
R&D129.61M143.12M214.36M305.65M436.53M590.39M693.26M942.24M1.61B1.44B1.19B1.05B
R&D as % of Total Revenue3.13%2.93%3.50%3.94%4.54%4.59%4.19%4.11%4.10%3.72%3.13%2.43%
Interest Expense031.36M16.36M53.46M99.41M128.02M201.05M136.54M206.39M120.28M293.22M298.25M
Interest Expense % of Total Revenue0.00%0.64%0.27%0.69%1.03%0.99%1.22%0.60%0.52%0.31%0.77%0.69%

Balance Sheet

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.56B9.69B10.59B12.58B23.37B29.24B46.29B55.13B64.69B73.67B80.33B103.12B
Total Liabilities2.66B3.26B4.53B5.84B4.82B11.83B13.57B16.37B17.76B18.15B21.24B22.87B
Total Equity2.60B3.37B5.57B6.34B17.66B17.31B32.49B38.49B46.59B55.12B58.63B79.71B
Cash762.17M1.00B2.51B2.47B5.76B5.23B10.24B8.24B7.99B13.76B19.56B29.47B
Total Debt1.14B175.25M492.84M1.64B1.85B7.52B5.93B5.62B6.99B5.45B4.75B8.42B
Net Debt377.82M-827.00M-2.02B-837.22M-3.91B2.29B-4.31B-2.62B-992.66M-8.31B-14.81B-21.05B

Cash Flow

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow712.55M738.60M1.76B1.79B1.64B2.92B3.97B4.59B10.62B13.39B12.41B17.59B
Investing Cash Flow-1.07B-933.28M-206.31M-1.12B-5.28B-4.97B-8.78B-4.84B-9.69B-7.56B-5.52B-2.43B
Financing Cash Flow656.47M428.51M-127.67M-674.17M6.98B1.56B9.89B-1.72B-1.28B-3.94B-3.83B1.22B
Capital Expenditure648.16M928.83M957.68M1.36B2.25B2.53B3.03B6.94B9.97B5.52B4.00B5.54B
Free Cash Flow64.39M-190.23M799.11M430.33M-608.47M384.23M942.69M-2.35B650.34M7.87B8.40B12.05B
Dividends Paid13.83M34.77M46.01M40.31M83.35M730.48M638.12M912.74M1.60B2.76B3.08B4.88B
FCF to OCF9.04%-25.76%45.49%23.99%-37.09%13.18%23.72%-51.14%6.13%58.79%67.73%68.52%
Dividend Paid to FCF21.48%-18.28%5.76%9.37%-13.70%190.11%67.69%-38.89%245.78%35.01%36.71%40.44%

Earnings

Report DateAug 23, 2018Oct 30, 2018Mar 22, 2019Apr 30, 2019Aug 19, 2019Oct 30, 2019Mar 24, 2020Apr 30, 2020Jul 20, 2020Oct 29, 2020Mar 30, 2021Apr 30, 2021Aug 12, 2021Oct 29, 2021Feb 15, 2022Apr 25, 2022Jul 26, 2022Oct 26, 2022Mar 20, 2023Apr 24, 2023Jul 31, 2023Oct 30, 2023Mar 18, 2024Apr 29, 2024Jul 30, 2024Oct 28, 2024Mar 17, 2025Apr 28, 2025Jul 28, 2025Oct 26, 2025Mar 23, 2026Apr 27, 2026Aug 3, 2026Oct 26, 2026
EPS Estimate--0.210.200.200.240.180.150.160.180.290.350.260.100.290.350.490.580.530.500.750.740.800.760.700.930.971.310.810.941.061.351.071.341.91
EPS Actual0.360.320.140.180.190.260.070.110.270.230.190.510.300.340.530.530.950.790.710.720.991.001.060.660.830.771.020.941.021.241.421.572.201.99
Surprise-252.38%-30.00%-10.00%-20.83%44.44%-53.33%-31.25%50.00%-20.69%-45.71%96.15%200.00%17.24%51.43%8.16%63.79%49.06%42.00%-4.00%33.78%25.00%39.47%-5.71%-10.75%-20.62%-22.14%16.05%8.51%16.98%5.19%46.73%64.18%4.19%
Timing-After-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap411.72B
Enterprise Value394.75B
Trailing P/E15.52
Forward P/E14.41
Price / Sales7.34
Price / Book4.45
EPS8.74
Book Value33.58
Revenue (TTM)56.10B
Gross Profit (TTM)30.60B
EBITDA28.86B
Profit Margin47.19%
Operating Margin45.00%
Return on Equity29.96%
Return on Assets14.30%
Shares Outstanding2.47B
Shares Float2.43B
Beta0.61
Dividend Yield1.51%
Dividend Rate2.09
Payout Ratio23.34%

Dividends

20231×
0.89Jun 14, 2023
20221×
0.52Jun 9, 2022
20211×
0.36Jun 8, 2021
20201×
0.28Jun 4, 2020
20191×
0.35Jul 2, 2019

Stock Splits

  • Jun 8, 20216:5
  • Jun 4, 20207:5
  • Jul 2, 2019188394:134567